378 related articles for article (PubMed ID: 16598738)
1. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
Porter MP; Stanford JL; Lange PH
Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
3. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
5. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
7. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002.
Saraiya M; Kottiri BJ; Leadbetter S; Blackman D; Thompson T; McKenna MT; Stallings FL
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2178-82. PubMed ID: 16172229
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey.
Bunker CH; Patrick AL; Konety BR; Dhir R; Brufsky AM; Vivas CA; Becich MJ; Trump DL; Kuller LH
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):726-9. PubMed ID: 12163325
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
10. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study.
Yang WJ; Lee DH; Chung BH; Cho JS; Choi YD; Kim SJ; Cho IR; Kim HS; Kim CI; Hong SJ;
Urology; 2006 Feb; 67(2):333-6. PubMed ID: 16461083
[TBL] [Abstract][Full Text] [Related]
11. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
[TBL] [Abstract][Full Text] [Related]
15. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
18. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Schröder FH; Roobol MJ
Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening with prostate-specific antigen in hemodialysis patients.
Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T
Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
